Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, ALL, AML, B Cell Lymphoma, Burkitt Lymphoma, Chronic Myelogenous Leukemia, CML, Cutaneous B-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hematologic Malignancy, Hodgkin Lymphoma, Leukemia, Lymphoma, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, T-cell Lymphoma
Conditions
Keywords
Venetoclax, Pediatric AML, Pediatric Relapsed/Refractory AML
Brief summary
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution Secondary Objectives * To evaluate the safety of crushed venetoclax tablets administered as an oral solution * To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors * To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube) * To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
Detailed description
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
Interventions
OTHER1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 38 Years
Healthy volunteers
No
Inclusion criteria
* Age: Patients must be \<39 years of age at time of study enrollment * Diagnosis: Patients may have a diagnosis of any hematologic malignancy * Central access: Patients must have an existing venous or arterial access line for PK blood draws * Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment * Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist. * Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion criteria
* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax. * Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clearance (CL) as measured by PK sampling (Peripheral Blood; Required) | Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax. | PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
| Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional) | Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points. | PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Countries
United States
Contacts
CONTACTSite Public Contact
PRINCIPAL_INVESTIGATORLauren Pommert, MD
Children's Hospital Medical Center, Cincinnati
Outcome results
None listed